Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

Open access
Ploussard, Guillaume, Terry, Stéphane, Maillé, Pascale, Allory, Yves, Sirab, Nanor, Kheuang, Laurence, Soyeux, Pascale, Nicolaiew, Nathalie, Coppolani, Estelle, Paule, Bernard, Salomon, Laurent, Culine, Stéphane, Buttyan, Ralph, Vacherot, Francis, de la Taille, Alexandre·2010·Cancer Research

Abstract

Expression of class III β-tubulin (βIII-tubulin) correlates with tumor progression and resistance to taxane-based therapies for several human malignancies, but its use as a biomarker of tumor behavior in prostate cancer (PCa) remains largely unexplored. Here, we describe βIII-tubulin immunohistochemical staining patterns of prostate tumors obtained from a broad spectrum of PCa patients, some of whom subsequently received docetaxel therapy for castration-resistant PCa (CRPC). Elevated βIII-tubulin expression was significantly associated with tumor aggressiveness in PCa patients with presumed localized disease, as it was found to be an independent marker of biochemical recurrence after treatment. Additionally, βIII-tubulin expression in tumor cells was an independent predictor of lower overall survival for patients receiving docetaxel-based chemotherapy for CRPC. Manipulation of βIII-tubulin expression in human PCa cell lines using a human βIII-tubulin expression vector or βIII-tubulin small interfering RNA altered cell survival in response to docetaxel treatment in a manner that supports a role for βIII-tubulin expression as a mediator of PCa cell resistance to docetaxel therapy. Our findings suggest a role for βIII-tubulin as candidate theranostic biomarker to predict the response to docetaxel-based chemotherapy as well as to target for treatment of docetaxel-resistant CRPC. Cancer Res; 70(22); 9253–64. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-1447

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 161

Metadata

Authors
Ploussard, G., Terry, S., Maillé, P., Allory, Y., Sirab, N., Kheuang, L., Soyeux, P., Nicolaiew, N., Coppolani, E., Paule, B., Salomon, L., Culine, S., Buttyan, R., Vacherot, F., & de la Taille, A.
Venue
Cancer Research
Published
2010-11-14
Volume
70
Issue
22
Pages
9253-9264
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2097694375
Cited by
161
References
2
FWCI
5.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-1447
The paper
Ploussard, G., Terry, S., Maillé, P., Allory, Y., Sirab, N., Kheuang, L., Soyeux, P., Nicolaiew, N., Coppolani, E., Paule, B., Salomon, L., Culine, S., Buttyan, R., Vacherot, F., & de la Taille, A. (2010). Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-1447

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.